Skip to main content

Travere Therapeutics, Inc. (TVTX)

NASDAQ: TVTX · IEX Real-Time Price · USD
26.17
-0.11 (-0.42%)
After-hours:Oct 22, 2021 4:21 PM EDT
26.28
1.05 (4.16%)
At close: Oct 22, 4:00 PM
Market Cap1.55B
Revenue (ttm)204.15M
Net Income (ttm)-237.05M
Shares Out60.57M
EPS (ttm)-4.33
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume537,626
Open25.11
Previous Close25.23
Day's Range24.76 - 26.73
52-Week Range12.75 - 33.09
Beta0.71
AnalystsStrong Buy
Price Target32.71 (+24.5%)
Est. Earnings DateOct 28, 2021

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thio...

IndustryBiotechnology
Employees262
Stock ExchangeNASDAQ
Ticker SymbolTVTX
Full Company Profile

Financial Performance

In 2020, TVTX's revenue was $198.32 million, an increase of 13.11% compared to the previous year's $175.34 million. Losses were -$169.43 million, 15.7% more than in 2019.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price forecast is 32.71, which is an increase of 24.47% from the latest price.

Price Target
$32.71
(24.47% upside)
Analyst Consensus: Strong Buy

News

Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago - Zacks Investment Research

Travere Therapeutics to Report Third Quarter 2021 Financial Results

SAN DIEGO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the close o...

1 week ago - GlobeNewsWire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2021, the Compensation Committee of its Board of Directors granted inducement e...

1 week ago - GlobeNewsWire

Travere Therapeutics Announces Transition of Chief Medical Officer

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief medical officer, Noah Rosenberg, M.D., has chosen to transition for personal reasons...

1 week ago - GlobeNewsWire

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe,...

ST. GALLEN, Switzerland & SAN DIEGO, Calif.--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced...

1 month ago - Business Wire

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe,...

Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand

1 month ago - GlobeNewsWire

Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors

Ms. Williams-Brinkley brings more than 35 years of executive leadership experience in healthcare to the Travere Board Ms. Williams-Brinkley brings more than 35 years of executive leadership experience i...

1 month ago - GlobeNewsWire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2021, the Compensation Committee of its Board of Directors granted inducemen...

1 month ago - GlobeNewsWire

See Why Travere Therapeutics Stock Moving Higher On Tuesday

Travere Therapeutics Inc (NASDAQ: TVTX) has concluded a Type A meeting with the FDA related to sparsentan in focal segmental glomerulosclerosis (FSGS).  See:   Travere Therapeutics' Sparsentan Program S...

1 month ago - Benzinga

Travere (TVTX) Announces Data on Rare Kidney Disease Drug

Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises

2 months ago - Zacks Investment Research

Here's Why Travere Therapeutics Stock Is Climbing Today

Investors are cheering positive phase 3 trial results with sparsentan that suggest it could become an important new treatment for a rare kidney disease.

2 months ago - The Motley Fool

TVTX Stock: Why Travere Therapeutics Stock Is Rocketing Higher Today

Travere Therapeutics (TVTX) stock is on the rise Monda and it's all thanks to positive interim results from one of its clinical trials. The post TVTX Stock: Why Travere Therapeutics Stock Is Rocketing H...

2 months ago - InvestorPlace

Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease Candidate

Compared to the active control irbesartan, the study met its pre-specified interim primary efficacy endpoint, demonstrating a more than threefold reduction of proteinuria from baseline after 36 weeks of...

2 months ago - Benzinga

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of 12.33% and 8.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Travere Therapeutics: Q2 Earnings Insights

Shares of Travere Therapeutics (NASDAQ:TVTX) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 77.27% over the past year to ($0.39),...

2 months ago - Benzinga

Travere Therapeutics Reports Second Quarter 2021 Financial Results

Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021

2 months ago - GlobeNewsWire

Earnings Preview: Travere Therapeutics (TVTX) Q2 Earnings Expected to Decline

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Travere Therapeutics to Report Second Quarter 2021 Financial Results

SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close of ...

3 months ago - GlobeNewsWire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2021, the Compensation Committee of its Board of Directors granted inducement equi...

3 months ago - GlobeNewsWire

New Strong Sell Stocks for June 25th

CVGW, KDNY, CMTL, GPL and TVTX have been added to the Zacks Rank #5 (Strong Sell) List on June 25, 2021.

Other symbols:CMTLCVGWGPLKDNY
3 months ago - Zacks Investment Research

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investo...

4 months ago - Newsfile Corp

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in June:

4 months ago - GlobeNewsWire

Why Travere Therapeutics Stock Is Plummeting Today

The FDA quashes the company's hopes for accelerated approval of a key pipeline drug.

4 months ago - The Motley Fool

Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data

Following the pre-NDA meeting, the FDA has asked Travere Therapeutics Inc (NASDAQ: TVTX) to submit additional data for the sparsentan program in focal segmental glomerulosclerosis (FSGS), characterized ...

4 months ago - Benzinga

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

Conference call and webcast to be held at 4:30p.m. ET Conference call and webcast to be held at 4:30p.m. ET

4 months ago - GlobeNewsWire